Reader-Supported · Editorially Reviewed
Evidence Watch · Peer-reviewed higher-dose trial

18.7% Average Loss With Semaglutide 7.2 mg at 72 Weeks

STEP UP compared a weekly 7.2 mg semaglutide regimen with 2.4 mg and placebo in adults with obesity without diabetes. Its 72-week results describe dose-specific trial averages under a defined protocol—not an individual outcome forecast or evidence that every provider offers the studied dose.

Last reviewed September 2026
1 study cited
The Lancet Diabetes & EndocrinologyPhase 3b, multicenter, double-blind, randomized, placebo- and active-controlled trial72 weeks
The study result

At week 72, mean body-weight change was −18.7% with semaglutide 7.2 mg, −15.6% with 2.4 mg, and −3.9% with placebo.

The estimated treatment difference was −14.8 percentage points versus placebo and −3.1 percentage points versus 2.4 mg. Gastrointestinal adverse events occurred in 70.8% with 7.2 mg, 61.2% with 2.4 mg, and 42.8% with placebo.

Compare programs

Turn the study result into a better program comparison

If this higher-dose result prompts you to explore GLP-1 care, compare details the trial did not test: product availability, medication status, clinician access, titration support, public price terms, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.

01
WellMedr logo
WellMedr

From $49 – $129/mo · Editorial score 4.7/5

Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.

Semaglutide at WellMedr
02
Strut Health logo
Strut Health

From $149 – $399/mo · Editorial score 4.6/5

Semaglutide at Strut Health
03
Trimi logo
Trimi

From $99 – $125/mo · Editorial score 4.8/5

Tirzepatide at Trimi
04
Telos Rx logo
Telos Rx

From $49 – $399/mo · Editorial score 3.9/5

Tirzepatide at Telos Rx
05
HealthRx logo
HealthRx

From $99 – $209/mo · Editorial score 4.1/5

Semaglutide at HealthRx
06
Cielo Health logo
Cielo Health

From $115 – $299/mo · Editorial score 4.4/5

Tirzepatide at Cielo Health

We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology

Study details

Population
1,407 adults without diabetes and with BMI of at least 30; 1,005 received semaglutide 7.2 mg, 201 received 2.4 mg, and 201 received placebo
Follow-up
72 weeks
Treatment comparison
Once-weekly subcutaneous semaglutide 7.2 mg compared with semaglutide 2.4 mg or placebo, with lifestyle intervention
Study design
Phase 3b, multicenter, double-blind, randomized, placebo- and active-controlled trial
Care and plan considerations

A study result is not a personal treatment plan

This article does not determine whether a higher-dose semaglutide regimen is appropriate for an individual, what a provider can prescribe, or what an insurer will cover. The study did not compare online programs or pharmacies. Dose selection and product availability require a licensed clinician and current prescribing information.

Compare semaglutide and tirzepatide programs

What this result does not show

  • The 72-week trial does not establish durability of weight change or safety beyond that period, including after treatment discontinuation.
  • It enrolled adults with BMI of at least 30 and excluded diabetes, so results do not directly apply outside those characteristics.
  • The 5:1:1 allocation left smaller 2.4 mg and placebo groups, limiting precision for uncommon harms and some comparative safety differences.
  • The prespecified outcomes were body weight and weight-loss thresholds, not cardiovascular events, mortality, provider quality, or affordability.
  • Novo Nordisk funded the trial; related affiliations and disclosures appear in the peer-reviewed article.
Not sure which provider fits you? Take the 30-second quiz
Answer 4 quick questions to get a personalized provider match
Continue reading

Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.

All study updates
Study & references

Primary peer-reviewed source

Wharton et al., Lancet Diabetes & Endocrinology 2025 · STEP UP

Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.

Read the study at The Lancet Diabetes & Endocrinology